Raltitrexed induces mitochondrial‑mediated apoptosis in SGC7901 human gastric cancer cells

Xue,Song; Chen,Ying‑Xia; Qin,Shu‑Kui; Yang,Ai‑Zhen; Wang,Lin; Xu,Hai‑Jun; Geng,Hai‑Yun

doi:10.3892/mmr.2014.2438

Raltitrexed induces mitochondrial‑mediated apoptosis in SGC7901 human gastric cancer cells

Authors:
- Song Xue
- Ying‑Xia Chen
- Shu‑Kui Qin
- Ai‑Zhen Yang
- Lin Wang
- Hai‑Jun Xu
- Hai‑Yun Geng
View Affiliations

Affiliations: Department of Medical Oncology, 81 Hospital of PLA, 81 Clinical College, Anhui Medical University, Nanjing, Jiangsu 210002, P.R. China, Central Laboratory, 81 Hospital of PLA, 81 Clinical College, Anhui Medical University, Nanjing, Jiangsu 210002, P.R. China
Published online on: August 1, 2014 https://doi.org/10.3892/mmr.2014.2438
Pages: 1927-1934

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Raltitrexed is a specific inhibitor of thymidylate synthase (TS), which has been considered as a potential chemotherapeutic agent for the treatment of advanced gastric cancer. In the present study, the apoptosis mechanisms of raltitrexed in SGC7901 human gastric cancer cells were investigated. The cytotoxic activity of raltitrexed on SGC7901 cells was determined by cell counting kit‑8 (CCK‑8) assay. The CCK‑8 assay indicated that raltitrexed inhibits SGC7901 cell growth in a dose‑ and time‑dependent manner. The morphological changes were observed by fluorescent microscopy, and characteristic morphological changes, including nuclear shrinkage and apoptotic bodies, were observed following Hoechst 33258 staining. The effects on apoptosis, cell cycle, mitochondrial transmembrane potential and reactive oxygen species (ROS) were measured by flow cytometry. The analysis revealed that raltitrexed exerted a growth inhibitory effect by inducing time‑dependent apoptosis and cell-cycle arrest at the G0/G1 phase. In addition, a compromised mitochondrial membrane potential and overproduction of ROS demonstrated the involvement of the mitochondrial signaling pathway. Raltitrexed‑induced caspase‑3‑dependent apoptosis was identified using a caspase‑3 activity assay and pretreatment with the caspase‑3 inhibitor, Ac‑DEVD‑CHO (sequence, Ac-Asp-Glu-Val-Asp-CHO). The activity of caspase-3 was analyzed with a spectrometer. The protein expression levels of Bax, Bcl-2, cytochrome c, cleaved caspase-3 and TS were examined by western blot and the mRNA expression level of TS was detected by quantitative polymerase chain reaction. The analysis revealed that the protein levels of Bax, cytochrome c and cleaved caspase‑3 were significantly increased by raltitrexed, while Bcl‑2 expression levels were reduced. Furthermore, raltitrexed increased the expression of the TS protein and mRNA in a time‑dependent manner. These results indicate that raltitrexed induces the apoptosis of SGC7901 cells through the caspase‑3‑dependent mitochondrial signaling pathway and upregulates the expression of the TS protein and mRNA.

View Figures

View References

1	Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 24:2137–2150. 2006. View Article : Google Scholar
2	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
3	Saika K and Sobue T: Cancer statistics in the world. Gan To Kagaku Ryoho. 40:2475–2480. 2013.(In Japanese).
4	Siegel R, DeSantis C, Virgo K, et al: Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 62:220–241. 2012. View Article : Google Scholar : PubMed/NCBI
5	Paoletti X, Oba K, Burzykowski T, et al; GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 303:1729–1737. 2010. View Article : Google Scholar : PubMed/NCBI
6	Scartozzi M, Galizia E, Verdecchia L, et al: Chemotherapy for advanced gastric cancer: across the years for a standard of care. Expert Opin Pharmacother. 8:797–808. 2007.PubMed/NCBI
7	Reni M, Pasetto L, Aprile G, et al: Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. Br J Cancer. 94:785–791. 2006. View Article : Google Scholar : PubMed/NCBI
8	Jarmuła A: Antifolate inhibitors of thymidylate synthase as anticancer drugs. Mini Rev Med Chem. 10:1211–1222. 2010.PubMed/NCBI
9	Hagner N and Joerger M: Cancer chemotherapy: targeting folic acid synthesis. Cancer Manag Res. 2:293–301. 2010.PubMed/NCBI
10	Ransom D, Wilson K, Fournier M, et al: Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines. Ann Oncol. 25:117–121. 2014. View Article : Google Scholar
11	Bottomley A, Gaafar R, Manegold C, et al: EORTC Lung-Cancer Group; National Cancer Institute, Canada: Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study. J Clin Oncol. 24:1435–1442. 2006.
12	Galetta D, Giotta F, Rosati G, et al: Carboplatin in combination with raltitrexed in recurrent and metastatic head and neck squamous cell carcinoma: A multicentre phase II study of the Gruppo Oncologico Dell’Italia Meridionale (G.O.I.M.). Anticancer Res. 25:4445–4449. 2005.PubMed/NCBI
13	Lemaire L, Malet-Martino MC, de Forni M, Martino R and Lasserre B: Cardiotoxicity of commercial 5-fluorouracil vials stems from the alkaline hydrolysis of this drug. Br J Cancer. 66:119–127. 1992. View Article : Google Scholar : PubMed/NCBI
14	Deboever G, Hiltrop N, Cool M and Lambrecht G: Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity. Clin Colorectal Cancer. 12:8–14. 2013. View Article : Google Scholar : PubMed/NCBI
15	Lim SC, Parajuli KR, Duong HQ, Choi JE and Han SI: Cholesterol induces autophagic and apoptotic death in gastric carcinoma cells. Int J Oncol. 44:805–811. 2014.PubMed/NCBI
16	de Martel C, Forman D and Plummer M: Gastric cancer: epidemiology and risk factors. Gastroenterol Clin North Am. 42:219–240. 2013.PubMed/NCBI
17	Bozkurt O, Karaca H, Ciltas A, et al: Efficacy and safety of raltitrexed combinations with uracil- tegafur or mitomycin C as salvage treatment in advanced colorectal cancer patients: a multicenter study of Anatolian Society of Medical Oncology (ASMO). Asian Pac J Cancer Prev. 15:1845–1849. 2014. View Article : Google Scholar
18	Kelly C, Bhuva N, Harrison M, Buckley A and Saunders M: Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history. Eur J Cancer. 49:2303–2310. 2013. View Article : Google Scholar : PubMed/NCBI
19	Kosmas C, Kallistratos MS, Kopterides P, et al: Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol. 134:75–82. 2008. View Article : Google Scholar : PubMed/NCBI
20	Saif MW, Shah MM and Shah AR: Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin Drug Saf. 8:191–202. 2009. View Article : Google Scholar : PubMed/NCBI
21	Ferrari VD, Amoroso V, Valcamonico F, et al: Epirubicin, cisplatin, and raltitrexed in patients with advanced gastric and hepatobiliary carcinoma: a phase II study. Am J Clin Oncol. 27:445–448. 2004. View Article : Google Scholar : PubMed/NCBI
22	Schmid KE, Kornek GV, Schüll B, et al: Second-line treatment of advanced gastric cancer with oxaliplatin plus raltitrexed. Onkologie. 26:255–258. 2003. View Article : Google Scholar : PubMed/NCBI
23	Gao YH, Zhang HP, Yang SM, et al: Inactivation of Akt by arsenic trioxide induces cell death via mitochondrial-mediated apoptotic signaling in SGC-7901 human gastric cancer cells. Oncol Rep. 31:1645–1652. 2014.
24	Sinha K, Das J, Pal PB and Sil PC: Oxidative stress: the mitochondria-dependent and mitochondria-independent pathways of apoptosis. Arch Toxicol. 87:1157–1180. 2013. View Article : Google Scholar : PubMed/NCBI
25	Renault TT, Teijido O, Antonsson B, Dejean LM and Manon S: Regulation of Bax mitochondrial localization by Bcl-2 and Bcl-x(L): keep your friends close but your enemies closer. Int J Biochem Cell Biol. 45:64–67. 2013. View Article : Google Scholar : PubMed/NCBI
26	Debatin KM: Apoptosis pathways in cancer and cancer therapy. Cancer Immunol Immunother. 53:153–159. 2004. View Article : Google Scholar : PubMed/NCBI
27	Circu ML and Aw TY: Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med. 48:749–762. 2010. View Article : Google Scholar : PubMed/NCBI
28	Martinou JC and Youle RJ: Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev Cell. 21:92–101. 2011. View Article : Google Scholar : PubMed/NCBI
29	Volkmann N, Marassi FM, Newmeyer DD and Hanein D: The rheostat in the membrane: BCL-2 family proteins and apoptosis. Cell Death Differ. 21:206–215. 2014. View Article : Google Scholar : PubMed/NCBI
30	Hüttemann M, Pecina P, Rainbolt M, et al: The multiple functions of cytochrome c and their regulation in life and death decisions of the mammalian cell: From respiration to apoptosis. Mitochondrion. 11:369–381. 2011.PubMed/NCBI
31	Hüttemann M, Lee I, Grossman LI, Doan JW and Sanderson TH: Phosphorylation of mammalian cytochrome c and cytochrome c oxidase in the regulation of cell destiny: respiration, apoptosis, and human disease. Adv Exp Med Biol. 748:237–264. 2012.PubMed/NCBI
32	Chen M, Guerrero AD, Huang L, et al: Caspase-9-induced mitochondrial disruption through cleavage of anti-apoptotic BCL-2 family members. J Biol Chem. 282:33888–33895. 2007. View Article : Google Scholar : PubMed/NCBI
33	Ola MS, Nawaz M and Ahsan H: Role of Bcl-2 family proteins and caspases in the regulation of apoptosis. Mol Cell Biochem. 351:41–58. 2011. View Article : Google Scholar : PubMed/NCBI
34	Shen J, Wang H, Wei J, et al: Thymidylate synthase mRNA levels in plasma and tumor as potential predictive biomarkers for raltitrexed sensitivity in gastric cancer. Int J Cancer. 131:E938–E945. 2012. View Article : Google Scholar : PubMed/NCBI
35	Lee KH, Hur HS, Im SA, et al: RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase. Cancer Lett. 299:22–28. 2010. View Article : Google Scholar
36	Di Cresce C, Figueredo R, Ferguson PJ, Vincent MD and Koropatnick J: Combining small interfering RNAs targeting thymidylate synthase and thymidine kinase 1 or 2 sensitizes human tumor cells to 5-fluorodeoxyuridine and pemetrexed. J Pharmacol Exp Ther. 338:952–963. 2011.